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 Human CPCs produce predominantly
smooth muscle cells.
 CPCs can be redirected to the
cardiomyocyte fate by transient
activation followed by inhibition of
NOTCH signaling.
 Inhibition of NOTCH signaling during
differentiation represses MIR-143/145
expression and blocks smooth muscle
differentiation.
 Expression of the microRNAs is under
control of CARMEN, a long noncoding RNA
associated with an enhancer located in the
MIR-143/145 locus and target of NOTCH
signaling.
 The CARMEN/MIR-145/143 locus
represents a promising therapeutic target
to favor production of cardiomyocytes in
cell replacement therapies.anne Medical School, Lausanne,
rtment of Cardiovascular Surgery,
art by grants to Dr. Pedrazzini from
06340-128129) and by the Novartis
rs have reported that they have no
e 30, 2016.
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473SUMMARYThe mechanisms controlling differentiation in adult cardiac precursor cells (CPCs) are still largely unknown. In this study,
CPCs isolated from the human heart were found to produce predominantly smooth muscle cells but could be redirected
to the cardiomyocyte fate by transient activation followed by inhibition of NOTCH signaling. NOTCH inhibition repressed
MIR-143/145 expression, and blocked smooth muscle differentiation. Expression of the microRNAs is under control of
CARMEN, a long noncoding RNA associated with an enhancer located in the MIR-143/145 locus and target of NOTCH
signaling. The CARMEN/MIR-145/143 axis represents, therefore, a promising target to favor production of cardiomyocytes
in cell replacement therapies. (J Am Coll Cardiol Basic Trans Science 2016;1:472–93) © 2016 The Authors. Published by
Elsevier on behalf of the American College of Cardiology Foundation. This is an open access article under the CC BY-NC-ND





CPC = cardiac precursor cell
DLL1 = Delta-like1
GO = gene ontology
J1 = Jagged1
lncRNA = long noncoding RNA
miRNA = microRNA
NICD = NOTCH intracellular
domain
RT-PCR = reverse transcriptionT he adult human heart has poor regenerativepotential, and heart failure gradually de-velops following injury (1,2). Ultimately,
heart transplantation represents the only therapeutic
option for end-stage heart failure. Within this
context, stimulation of cardiomyocyte production in
the damaged heart to promote regeneration repre-
sents an attractive therapeutic approach (3,4). In
particular, cell replacement therapy via injection of
precursor cells into the damaged heart represents an
interesting therapeutic avenue. The main challenge
for transferring cell therapies for heart disease into
a clinical setting is to identify a suitable source of hu-
man cardiac precursor cells (CPCs). Direct isolation of
CPCs from the heart of cardiac patients would repre-
sent a great advantage by the autologous nature of
the isolated cells. This would indeed reduce the prob-
lems associated with immune rejection. The exis-
tence of resident CPCs in the adult mammalian
heart, including the human heart, capable of differen-
tiating into functional cardiomyocytes, has been
demonstrated (3,4). However, the number of CPCs
in the adult myocardium is quite low, and isolation
of these cells is a challenging procedure. Indeed, no
truly speciﬁc markers are currently available to
distinguish CPCs from other cell types (3,4). Multipo-
tent mesenchymal stromal cells expressing cardiac
transcription factors such as GATA4, NKX2.5, and
MEF2C, but no proteins expressed by fully differenti-
ated cardiomyocytes such as proteins of the sarco-
mere, could therefore be operationally deﬁned as
CPCs. Nevertheless, the effective generation of new
cardiomyocytes from transferred CPCs is still a matter
of intense debate, and restoration of function has
been attributed to paracrine mechanisms mediated
by factors secreted from the transferred cells (2–4).
Therefore, a clear understanding of the regulatory
networks controlling mobilization and differentiation
of endogenous CPCs toward the cardiac lineage isrequired in order to facilitate the ultimate goal of car-
diac regeneration.
Several pathways that are important during cardiac
morphogenesis are reactivated in the damaged
myocardium. Among these, the NOTCH pathway plays
crucial roles in the developing and adult heart (5,6).
NOTCH is an evolutionarily conserved cell-to-cell
communication system that takes place between 2
adjacent cells (7). The signal-sending cell expresses a
membrane-bound ligand such as Jagged (J)1, J2, Delta-
like1 (DLL1), DLL3, and DLL4, and the signal-receiving
cell expresses a NOTCH receptor such as NOTCH (N)1,
N2, N3, and N4. Receptor engagement results in its
cleavage and liberation of the NOTCH intracellular
domain (NICD). NICD translocates into the nucleus,
where it interacts with co-activators, in particular a
transcription factor known as RBPJ, to activate target
gene expression. NOTCH target genes include re-
pressors of the Hairy enhancer of split (HES) and the
related HEY families (8). During development, NOTCH
regulates trabeculation, myocyte proliferation, and
valve formation. In theneonatal heart,NOTCHcontrols
cardiac precursor expansion and differentiation (9). In
theadultheart,NOTCHsignaling isactivated in
cardiomyocytes, CPCs, and ﬁbroblasts (10–14).
Interestingly, NOTCH appears to prevent pre-
mature cardiogenic differentiation in precur-
sor cells, and to favor proliferation in this
transient amplifying cell compartment (14).
Consistent with this observation, blockade of
the NOTCH pathway in embryonic stem cells
favors commitment into the cardiac meso-
derm, and subsequently, into cardiomyocytes,
at the expense of the neuroectodermal lineage
(15). NOTCH signaling has also been reported
to induce early cardiac commitment in em-
bryonic and induced pluripotent stem cells,
supporting a biphasic role of NOTCH in car-
diogenesis (16). Accordingly, NOTCH signalingpolymerase chain reaction
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natal heart (17,18). Furthermore, NOTCH has been
implicated in the differentiation of cardiosphere-
derived cells into smoothmuscle cells (19). Thisﬁnding
is reminiscent of the role of NOTCH in vascular smooth
muscle cells, in which Jagged1-activated NOTCH
signaling promotes a differentiated phenotype (20).
Interestingly, NICD, associated with RBPJ, binds to
an enhancer within the locus encoding the small regu-
latory noncoding RNAs MIR-143/145, 2 microRNAs
(MIRs) that were previously shown to regulate smooth
muscle cellphenotypeandbehavior (20,21).
In recent years, it has become apparent that the
noncoding genome is pervasively transcribed,
generating thousands of long noncoding RNAs
(lncRNAs). These transcripts, which are deﬁned as
being >200 nucleotides in length with no apparent
protein coding potential, are typically expressed in a
highly cell- and context-speciﬁc manner. LncRNAs
are emerging, therefore, as master regulators of gene
expression and important mediators of lineage-
speciﬁc commitment during development (22,23). In
the developing and adult hearts, lncRNAs are
dynamically expressed and exert control of the car-
diac gene regulatory network (24–26). A growing body
of evidence suggests that they could be pivotal during
the pathophysiological response in the damaged
heart (27,28). LncRNAs efﬁciently operate in cis, at
the site of transcription, and in trans, at remote lo-
cations in the genome. In particular, lncRNAs, which
are transcribed from active enhancers, contribute to
neighboring gene activation via cis mechanisms
(29,30). In this context, we recently identiﬁed CAR-
MEN [(CAR)diac (M)esoderm (E)nhancer-associated
(N)oncoding RNA], a lncRNA that is a crucial regulator
of cardiac speciﬁcation in human CPCs isolated from
the fetal heart (31,32). Interestingly, CARMEN is
templated from the NOTCH-responsive enhancer
element within the MIR-143/145 locus. In the present
study, we aimed at evaluating the cardiogenic po-
tential of CPCs isolated from adult human hearts. We
show that human clonogenic CPCs can be readily
obtained from atrial appendages, expanded in vitro,
and induced to differentiate into either smooth
muscle cells or cardiomyocytes. This binary cell fate
decision depends on the state of activation or inhi-
bition of the NOTCH pathway. Activation of NOTCH
signaling promotes adoption of a smooth muscle
lineage, whereas sequential activation and inhibition
favor cardiomyocyte speciﬁcation. NOTCH signaling
appears to target CARMEN in differentiating CPCs.
More precisely, we demonstrated that a particular
CARMEN isoform regulates commitment into the
smooth muscle fate. Therefore, NOTCH inhibition, viadown-regulation of the smooth muscle cell–speciﬁc
isoform of CARMEN, represses MIR-143/145 expres-
sion, and forces CPCs to adopt a cardiomyocyte fate.
METHODS
CULTURE OF HUMAN ADULT CPCs. Human atrial
appendages were obtained from male patients (35 to
90 years old) undergoing cardiac surgery through
donation.Theprotocol receivedauthorization fromthe
UniversityHospital EthicsCommittee and theCantonal
Ethics Committee on research involving humans.
Tissues were minced and enzymatically digested in a
buffer containing 0.45 mg/ml collagenase (Wor-
thington Biochemical Corporation, Lakewood, New
Jersey) and 1 mg/ml pancreatin (Invitrogen, Carlsbad,
California) (Supplemental Figure 1A). Following 24
hours inculture, cells that remained insuspensionwere
discarded, and adherent cells were expanded in
expansion medium (3:1 DMEM 1g/l glucose/Medium
199 [Invitrogen] supplemented with 10% horse serum
[Serotec, Kidlington,UnitedKingdom], 5% fetal bovine
serum [Serotec], 100 U/ml penicillin [Invitrogen], and
100 mg/ml streptomycin [Invitrogen]). For inducing
differentiation, cells were switched to MEM alpha
(Invitrogen) containing 2% horse serum, 1 mmol/l
dexamethasone (Sigma-Aldrich, St. Louis, Missouri),
50 mg/ml ascorbic acid (Sigma-Aldrich), 10 mmol/l
b-glycerophosphate (Sigma-Aldrich), 100 U/ml peni-
cillin (Invitrogen), and 100 mg/ml streptomycin
(Invitrogen) (differentiation medium [33]), and
cultured for 2 to 3 weeks before analysis.
EXPERIMENTS IN SCID NEONATES. Immunodeﬁ-
cient SCID mice (S/B6.CB17-PrKdc scid Ma SN1913, The
Jackson Laboratory, Bar Harbor, Maine) were used in
cell transfer experiments. Animal experiments were
approved by the Government Veterinary Ofﬁce
(Lausanne, Switzerland) and performed according to
the guidelines from Directive 2010/63/EU of the
European Parliament. Mice were maintained under
speciﬁc pathogen-free conditions. CPCs were either
not stimulated (None) or exposed to DLL1 for 24h. Cells
(105 in 50 ml NaCl 0.09%) were injected into neonatal
mice through the superﬁcial temporal vein. Twenty-
four hours post cell-injection, the test group was
injected with DAPT [N-(N-(3,5-diﬂuorophenacetyll)-
L-alanyl)S-phenylglycine t-butyl ester] diluted in
dimethyl sulfoxide (DMSO) (4 ml/g of body weight/
day), whereas the control group received DMSO only
(No DAPT group) for 3 consecutive days. Twelve days
post-injection, hearts were collected and embedded in
optimal cutting temperature compound. To identify
heart sections containing human cells, every second
cryosection was collected for reverse transcription
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475polymerase chain reaction (RT-PCR) detection of the
human a-satellite chromosome (8 sections per PCR
tube). SectionsweredigestedwithProteinaseK (Sigma-
Aldrich) in Direct PCR Tail Buffer (Viagen Biotech, Los
Angeles, California). DNAwas ampliﬁed using TaqNEB
(New England Biolabs, Ipswich, Massachusetts). The
primers are described in the Supplemental Methods.
Immunostaining directed against human LAMIN and
a-ACTININ was performed. The surface of the LAMIN
area was measured using confocal images and the
ImageJ application (Version 1.50B, National Institutes
of Health, Bethesda, Maryland). Tridimensional vol-
umes were reconstructed using IMARIS software
(Version 7.7.1, Bitplane, Belfast, United Kingdom).
RNA SEQUENCING AND ANALYSIS. Total RNA was
isolated from proliferating and differentiated CPCs
using the RNeasy isolation kit (Qiagen, Valencia,
California). Sequencing libraries were prepared ac-
cording to Illumina RNA Seq library kit instructions
with Poly(A) selection (Illumina, San Diego, Califor-
nia). Libraries were sequenced with the Illumina
HiSeq2000 (2  100 bp).
STATISTICAL ANALYSIS. All data were collected from
at least 3 independent experiments, performed in
triplicate. Data throughout the paper are expressed as
mean  SEM. Data were processed using GraphPad
Prism (version 7.00, GraphPad Software, La Jolla, Cal-
ifornia), and analyzed by theKolmogorov-Smirnov test
to check for normal distribution. Analysis was per-
formed using analysis of variance with post hoc Tukey
test. For non-normally distributed data, Kruskal-
Wallis analysis with the Dunn multiple comparison
test were used, and median values were calculated.
Values of p < 0.05 were considered signiﬁcant.
For transcriptomic data, statistical analysis was
performed in R version 3.0.2 (R Foundation for
Statistical Computing, Vienna, Austria). Raw counts
were normalized using TMM (EdgeR, R version 3.4.0
[34]) for genes with 1 count per million (cpm) in at
least 1 sample. Log transformation was applied on the
normalized counts using Voom function (limma
package, R version 3.18.2 [35]). Differential expres-
sion was computed with limma (36), and a moderated
t test was used for each comparison. Adjusted
p values were computed by the Benjamini-Hochberg
method, controlling for a false discovery rate.
An expanded methods section is also available in
the Supplemental Appendix.
RESULTS
CHARACTERIZATION OF CARDIAC PRECURSOR
CELLS ISOLATED FROM ADULT HUMAN ATRIAL
APPENDAGES. Human CPCs were isolated from rightatrial appendages of male patients (35 to 86 years old)
undergoing cardiac surgery (Supplemental Figure 1A).
Following expansion in vitro, we routinely obtained
several 100 thousand cells from each biopsy
(Supplemental Table 1). Cells could be stored frozen,
thawed, and retained a proliferative capacity for more
than 15 passages. We ﬁrst measured the expression of
markers of cardiac speciﬁcation and differentiation
by RT-PCR (Figure 1A). Under expansion conditions,
these cells expressed early cardiac markers such as
GATA4, NKX2.5, and MEF2C, but no markers of
differentiated cardiomyocytes such as a-myosin
heavy chain (MYH6), b-myosin heavy chain (MYH7),
cardiac actin (ACTA), or cardiac troponin I (TNNI). We
examined cell surface marker expression by ﬂow
cytometry (Figure 1B). The cells uniformly expressed
mesenchymal stem cell markers such as CD73, CD90,
and CD105, whereas endothelial and hematopoietic
markers (CD31, CD34, CD45), CD117 (KIT), CXCR4, and
CD140 (PDGFRa) were not expressed. A signiﬁcant
proportion expressed CD146, suggesting that they
could derive from pericytes (37). However, these cells
did not express NG2, another pericyte marker. The
characteristics of the isolated cells were further
investigated by immunostaining. All cells were found
positive for NKX2.5 (Figure 1C). In addition, NKX2.5-
positive (NKX2.5POS) cells were MEF2CPOS. The vast
majority of NKX2.5POS cells (73%) also expressed
GATA4. Proliferation was examined using immuno-
staining directed against the proliferation markers
Ki67 and phospho-Histone 3 (PH3). Respectively, 37%
and 24% of NKX2.5POS were found Ki67POS and
pH3POS. Altogether, these data indicated that the
isolated population was composed of proliferative
CPCs from mesenchymal origin, which are referred
throughout this paper as adult CPCs. Interestingly,
adult CPCs exhibited similar characteristics as CPCs
previously isolated from the human fetal heart, which
were shown to produce fully differentiated car-
diomyocytes (31).
HUMAN ADULT CPCs DIFFERENTIATE PRIMARILY
INTO SMOOTH MUSCLE CELLS. To examine the
potential of adult CPCs for producing a differentiated
progeny, cells were exposed to a differentiation
medium shown to induce robust cardiomyocyte dif-
ferentiation in human fetal CPCs (31,33). Under these
conditions, however, adult CPCs produce exclusively
smooth muscle cells (Supplemental Figures 1B
and 1C). Three weeks after inducing differentiation,
expression of smooth muscle myosin heavy chain
(MYH11) was signiﬁcantly increased. In addition, 80%
of the cells were smooth muscle-myosin heavy
chain (SM-MHC)POS by immunostaining, whereas
<1% stained positive for the cardiomyocyte-speciﬁc
FIGURE 1 Characterization and Differentiation of Adult CPCs
(A) Expression of early (GATA4, MEF2C, NKX2.5) and late cardiac markers (MYH6, MYH7, TNNI, CX43) in the human adult heart and in isolated cardiac precursor cells
(CPCs). (B) Flow cytometry analysis of CD31, CD34, CD45, CD73, CD90, CD105, CD117, CXCR4, CD140a, CD146, and NG2 expression in adult CPCs. Histograms show
control (gray) and speciﬁc ﬂuorescent intensity signal (white). (C) Analysis of cardiac transcription factor and proliferation marker expression by immunostaining. Nuclei
were stained with DAPI (blue). Scale bar: 20 mm. Quantiﬁcation of NKX2.5POS/GATA4POS, NKX2.5POS/MEF2CPOS, NKX2.5POS/PH3POS, and NKX2.5POS/KI67POS CPCs. Data
represent mean  SEM (minimum 4,000 cells in 50 different ﬁelds at a magniﬁcation of 40 per quantiﬁcation). (D) Gene expression of MYH6, MYH7, TNNI, ACTA, and
MYH11 in proliferating CPCs (Expansion; black) and in adult CPCs exposed to DLL1 (gray), and differentiated in the absence (upper panels) or presence of DAPT
(lower panels). Data represent mean  SEM; *p < 0.05 as compared with proliferating CPCs; ‡p < 0.05 as compared with differentiating unstimulated (None; white)
CPCs in absence of DAPT (n ¼ 5). (E) Analysis of SM-MHC and a-ACTININ expression by immunostaining in CPCs exposed or not to DLL1 and differentiated in the absence
or presence of DAPT. Nuclei were stained with DAPI (blue). Scale bars: 20 mm. (F) Quantiﬁcation of SM-MHCPOS and a-ACTININPOS in adult CPCs exposed to DLL1 (gray),
and differentiated in the absence or presence of DAPT. Data represent mean  SEM; *p < 0.05 as compared with proliferating CPCs; ‡p < 0.05 as compared with
differentiating unstimulated (None) (white) CPCs in absence of DAPT (minimum 2,000 cells in 30 different ﬁelds at a magniﬁcation of 40 per quantiﬁcation).
Diff ¼ differentiation medium; Exp ¼ expansion medium.
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477marker a-ACTININ. Cardiac transcription factors
(GATA4, MEF2C, NKX2.5) and differentiation markers
(MYH6 and MYH7) were minimally induced. No
endothelial cells were detected in differentiating cell
cultures (data not shown). Therefore, adult CPCs
displayed limited cardiogenic potential under these
conditions, and differed markedly from fetal CPCs in
their capacity to produce cardiomyocytes (31). In or-
der to investigate the underlying mechanisms con-
trolling adult CPC differentiation, we ﬁrst compared
expression of various cardiac markers in adult vs.
fetal CPCs under basal and differentiation conditions.
Cardiac transcription factors (GATA4, MEF2C,
NKX2.5, and TBX5) were signiﬁcantly more expressed
in fetal than in adult CPCs, suggesting that fetal
CPCs are more committed to the cardiac lineage than
adult CPCs (Supplemental Figure 1D). Furthermore,
MYH6 and MYH7 were signiﬁcantly induced in
fetal CPCs upon differentiation, whereas these genes
were not activated in adult CPCs (Supplemental
Figure 1E). On the contrary, MYH11 expression was
induced in adult CPCs during the differentiation
process.
NOTCHACTIVATIONSTIMULATESCARDIAC TRANSCRIPTION
FACTOR EXPRESSION AND PROLIFERATION IN ADULT
CPCs. Because of the role of the NOTCH pathway in
cardiac precursor renewal and differentiation during
development and in the adult heart, we measured
expression of NOTCH receptors and ligands in fetal
and adult CPCs (Supplemental Figure 2A). Although
expression of all NOTCH receptors was comparable
between fetal and adult CPCs, NOTCH ligands, i.e.,
J1, J2, DLL1, DLL3, and DLL4 were signiﬁcantly down-
regulated in adult CPCs. The levels of HES1 and HEY1
were also signiﬁcantly lower in adult CPCs, whereas
HEY2 was more expressed. These results led us to
postulate that activation of NOTCH signaling could
contribute to sustaining cardiogenesis in fetal CPCs.
Therefore, we investigated the possibility of restoring
a cardiogenic potential in adult CPCs via manipula-
tion of the NOTCH pathway. Adult CPCs were
cultured on immobilized DLL1 ligand to activate
NOTCH signaling (Supplemental Figure 2B). The ef-
ﬁciency of this procedure was demonstrated using
the hN1 reporter cell line, in which YFP expression is
driven by N1ICD/RBPJ (Supplemental Figure 2C) (38).
Activation of NOTCH signaling in adult CPCs exposed
to immobilized DLL1 was veriﬁed by the induction of
HES1, HEY1, and HEY2 transcription (Supplemental
Figure 2D). This manipulation had no signiﬁcant ef-
fect on expression of NOTCH receptors and ligands.
Exposure to DLL1 markedly stimulated proliferation
in adult CPCs as judged by expression of severalgenes encoding positive (CCND1, C-MYC, and
PCNA) and negative (CDKI1A) regulators of the cell
cycle (Supplemental Figure 2E). Consistently, EdU
(5-ethynyl-20-deoxyuridine) incorporation was also
higher in NOTCH-induced CPCs (Supplemental
Figure 2F). We next evaluated the impact of NOTCH
stimulation in adult CPCs on the expression of
cardiac transcription factors. DLL1-mediated NOTCH
activation induced a marked expression of GATA4,
NKX2.5, MEF2C, and TBX5 (Supplemental Figures 2G
and 2H). Importantly, exposure to DLL1 increased the
number of NKX2.5POS, GATA4POS, MEF2CPOS CPCs
(Supplemental Figure 2I).
SEQUENTIAL NOTCH ACTIVATION AND INHIBITION
IN ADULT CPCs FAVORS DIFFERENTIATION INTO
CARDIOMYOCYTES. To investigate whether the in-
crease in cardiac transcription factor expression
following NOTCH activation restored a cardiogenic
potential in adult CPCs, DLL1-stimulated CPCs were
cultured under differentiation conditions. However,
NOTCH-stimulated CPCs produced again exclusively
smooth muscle cells (Figures 1D [upper panel] to 1F).
Indeed, these cells demonstrated high MYH11
expression and no expression of cardiomyocyte
markers such as MYH6 and MYH7. As a consequence,
the vast majority of differentiated cells were
SM-MHCPOS, whereas none expressed a-ACTININ.
The action of NOTCH as an inducer of cardiac
commitment and proliferation is in accordance with
previous observations in CPCs and immature car-
diomyocytes (10,14,39,40). However, NOTCH also
exerts inhibitory actions on terminal cardiac differ-
entiation (10,15,40). Therefore, while promoting CPC
speciﬁcation, NOTCH could at the same time block
cardiomyocyte production from committed CPCs. To
examine this possibility, adult CPCs were exposed to
DLL1 and induced to differentiate in the presence of
DAPT, an inhibitor of gamma secretase and thereby of
the NOTCH pathway (Supplemental Figure 3A). DAPT
efﬁciently blocked NOTCH signaling during differen-
tiation as judged by the blunted expression of
NOTCH target genes in treated CPCs (Supplemental
Figure 3B). In sharp contrast to what was observed
in the absence of DAPT, a marked expression of car-
diac transcription factors and genes expressed in
terminally differentiated cardiomyocytes were
readily observed in NOTCH-inhibited CPCs, which
therefore produced a-ACTININPOS cardiomyocytes
and very few smooth muscle cells (Supplemental
Figure 3C, Figures 1D to 1F). Importantly, exposure
to DLL1 was a prerequisite for restoring the cardio-
genic potential in differentiating CPCs. Indeed, in the
absence of this sensitization step, adult CPCs gave
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These results underlined the importance of a tran-
sient NOTCH activation to promote cardiomyocyte
speciﬁcation. Moreover, we formally demonstrated
the dependence on the NOTCH1 signaling pathway for
specifying CPCs in the cardiomyocyte lineage by
taking advantage of selective inhibitory antibodies
directed against N1 (namely NRR1 [41]). Speciﬁc
blockade of NOTCH1-mediated pathways in dif-
ferentiating DLL1-sensitized CPCs was sufﬁcient for
producing cardiomyocytes (Supplemental Figure 3D).
These experiments rules out nonspeciﬁc effects of
DAPT in differentiating CPCs. Finally, it is important
to note that CPCs exposed to a different NOTCH
ligand, i.e., J1, were equally able to produce
cardiomyocytes following NOTCH inhibition
(Supplemental Figure 4). However, J1-activated CPCs
did not demonstrate increased proliferation. There-
fore, DLL1 was chosen for further experiments.
ADULT CPC–DERIVED CARDIOMYOCYTES EXHIBIT
FUNCTIONAL ELECTRICAL PROPERTIES. To func-
tionally characterize CPC-derived cardiomyocytes, we
ﬁrst measured expression of several calcium handling
proteins (Figure 2A). Expression of the L-type calcium
channel (CAV1.2), ryanodine receptor (RYR2), and
sarcoplasmic reticulum calcium ATPase (SERCA2B)
was induced in adult CPCs differentiating into car-
diomyocytes. Marginal expression was observed in
situations giving rise to smooth muscle cells. To
evaluate whether differentiating CPCs exhibited
electrophysiological properties, we assessed Ca2þ
signaling in resting and ﬁeld-stimulated cells
(Figure 2B). Under resting conditions or pacing (0.5
Hz), undifferentiated proliferating CPCs did not
exhibit any calcium transients. Similarly, the 2 groups
of differentiated cells did not show signiﬁcant spon-
taneous calcium response. By contrast, electrical
pacing triggered a marked and synchronized increase
in cytosolic Ca2þ in CPC-derived cardiomyocytes pro-
duced by exposure to DLL1 and the presence of DAPT
during differentiation. These ﬁndings were consistent
with cardiomyocytes exhibiting functional calcium-
induced calcium release when electrically stimu-
lated. These calcium signals appear to last longer than
those present in fully differentiated cardiomyocytes,
similar to observations made in differentiating
induced pluripotent stem cells (42). Although some
calcium transients were detected in CPC-derived
smooth muscle cells, the 2 differentiating pop-
ulations differed markedly in their capacity to
respond to electrical stimulation (Videos 1 and 2).
Quantiﬁcation of the response, as measured by
determining the number of responding cells,amplitude of the calcium transients, and time to reach
maximal Ca2þ release, supported electrical compe-
tence in CPC-derived cardiomyocytes as compared
with smooth muscle cells (Figure 2C). These data
demonstrated that the CPC-derived cardiomyocytes
developed electrical properties similar to those of
mature cardiomyocytes.
ADULT HUMAN CPCs PRODUCE CARDIOMYOCYTES
IN VIVO. To determine whether adult CPCs could
produce cardiomyocytes in vivo, cells were injected
into SCID mouse neonates intravenously. This pro-
tocol was previously demonstrated to result in sig-
niﬁcant engraftment and differentiation of CPCs in
the post-natal heart (33). Cells were, therefore, either
exposed or not to DLL1, and injected into neonatal
mice, which then were administered with DAPT
to favor cardiac differentiation (Supplemental
Figure 5A). Twelve days thereafter, hearts were
sectioned entirely and analyzed to determine the
degree of CPC engraftment and differentiation. We
ﬁrst used PCR to detect human satellite DNA in cry-
osections. Provided that CPCs were exposed to DLL1,
DAPT treatment promoted engraftment as shown by
the increased number of PCR-positive sections in the
relevant group (Supplemental Figure 5B). To further
quantify engraftment and differentiation of human
CPCs within the host myocardium, we performed
immunostaining directed against human (h)LAMIN
(human-speciﬁc antigen) and a-ACTININ (cardiac
marker). Occasional undifferentiated human CPCs
were detected in the hearts of mice receiving no DAPT
(Figure 2D). Similarly, in mice treated with DAPT but
injected with CPCs that were not exposed to DLL1,
hLAMINPOS cells did not differentiated into car-
diomyocytes (Supplemental Figure 5C). Strikingly, in
the group receiving DLL1-sensitized CPCs and treated
with DAPT, large clusters of hLAMINPOS human cells
expressing a-ACTININ were readily detected
(Figures 2D and 2E). Quantiﬁcation of hLAMIN area
conﬁrmed that numerous human cells engrafted in
the mouse myocardium under these conditions
(Figure 2F). To ascertain the degree of differentia-
tion of CPC-derived cardiomyocytes, we performed
confocal microcopy. Z-stack analysis across
hLAMINPOS human cardiomyocytes conﬁrmed coloc-
alization of hLAMIN and a-ACTININ (Supplemental
Figure 5D). Sarcomeric organization conﬁrmed that
transferred CPCs gave rise to mature cardiomyocytes.
Finally, we generated a tridimensional reconstruction
of areas containing human cardiomyocytes, which
supported functional integration of human car-
diomyocytes in the mouse myocardium (Figure 2G).
Altogether, these data indicated that NOTCH
FIGURE 2 Adult CPCs Produce Functional Cardiomyocytes In Vitro and In Vivo
(A) Expression of calcium handling proteins (CAV1.2, RYR2, SERCA2B) in proliferating CPCs (Expansion; black) and in adult CPCs exposed to DLL1 (gray), and differ-
entiated in the absence or presence of DAPT. Data represent mean  SEM; *p < 0.05 as compared with proliferating CPCs; ‡p < 0.05 as compared with differentiating
unstimulated (None; white) CPCs in absence of DAPT (n ¼ 4). (B) Cytosolic Ca2þ signals were recorded in adult CPCs in expansion (upper panels), and in differentiating
CPCs following exposure or not to DLL1 in the presence of DAPT. Cells were either evaluated under resting conditions or electrical stimulated (10 s at 0.5 Hz). Scale bar:
50 mm. Representative tracing of normalized Ca2þ changes obtained following induction of pacing (arrow). Colored lines correspond to regions of recording as indicated
in B. Images depicted in B were taken at the indicated time (*). See Videos 1 and 2. (C) Quantiﬁcation of calcium transient parameters. Data represent mean  SEM;
*p < 0.05 as compared with proliferating CPCs; ‡p < 0.05 as compared with differentiating unstimulated (None) (white) CPCs in absence of DAPT (n ¼ 55 cells per
quantiﬁcation). (D) Analysis of h-LAMIN (red) and a-ACTININ expression (green) in human CPC-derived cardiomyocytes in SCID mouse heart sections by immunostaining.
DLL1-stimulated CPCs were injected in neonatal SCID mice. Mice were injected with DAPT or vehicle alone. Nuclei were stained with DAPI (blue). Scale bars: 20 mm.
(E) High magniﬁcation of human hLAMINPOS a-ACTININPOS cardiomyocytes in the mouse myocardium. Scale bars: 20 mm. (F) Quantiﬁcation of human hLAMINPOS
cardiomyocyte patches in SCID mouse hearts. Data represent mean  SEM; *p < 0.05 as compared with control group (unstimulated CPCs [None]; No DAPT
administration); ‡p < 0.05 as compared with the group of animals injected with CPCs exposed to DLL1 (gray), but not injected with DAPT (minimum 3,000 cells in
40 different ﬁelds at a magniﬁcation of 40 per quantiﬁcation, 3 animals per condition). (G) Confocal analysis and tridimensional reconstruction of a representative
patch of human cardiomyocytes in the mouse myocardium. (a) Confocal image of a representative patch. Scale bars: 20mm. (b and c) Tridimensional reconstruction
of the representative human cardiomyocyte depicted in a. hLAMIN (red), a-ACTININ expression (green), DAPI (blue). Scale bar: 5 mm. (d and e) High magniﬁcations
of areas indicated in b and c. Scale bar: 20 mm. Abbreviations as in Figure 1.
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480signaling could be modulated in vivo to enhance
the speciﬁcation of adult CPCs towards the car-
diomyocyte fate.
NOTCH-DEPENDENTMIR-143/145 EXPRESSION CONTROLS
DIFFERENTIATION OF ADULT CPCs INTO SMOOTH MUSCLE
CELLS. Proliferation and differentiation of smooth
muscle cells has been shown to be regulated by MIR-
143/145 (20,21). We therefore measured MIR-143/145
expression in fetal and adult CPCs (Supplemental
Figure 6A). The expression levels of both microRNAs
(miRNAs) were strongly down-regulated in fetal CPCs
during spontaneous differentiation into car-
diomyocytes. In sharp contrast, expression was
markedly induced during differentiation of adult
CPCs, consistent with their preferential commitment
toward the smooth muscle cell lineage. We next eval-
uated whether MIR-143/145 expression was modu-
lated in adult CPCs according to their differentiation
into either cardiomyocytes or smooth muscle cells.
Adult CPCs were, therefore, induced to differentiate
following exposure to DLL1 in the presence or absence
of DAPT.MIR-143/145 expression was measured under
these different conditions (Figure 3A). Expression of
MIR-143/145 was robustly increased in all situations
giving rise to smooth muscle cells. On the contrary,
expression of the two miRNAs was signiﬁcantly
blunted in CPCs giving rise to cardiomyocytes. Target
genes of MIR-143/145, negatively controlling smooth
muscle cells differentiation, have been previously
identiﬁed (21). Expression of ETS-domain protein 1
(ELK1) and Krueppel-like factor 4 (KLF4) was, there-
fore, measured. ELK1 and KLF4 were found to be up-
regulated in adult CPCs differentiating into car-
diomyocytes, concomitantly with MIR-143/145 down-
regulation (Figure 3A). These results demonstrated
that MIR-143/145 were under control by the NOTCH
pathway in adult CPCs.
To further investigate the importance of MIR-143/
145 in lineage determination in adult CPCs, we used
anti-MIR LNA inhibitors and miRNA mimics to
modulate MIR-143/145 activity during adult CPC dif-
ferentiation. We ﬁrst cultured CPCs under conditions
that favor smooth muscle cell differentiation (i.e., no
exposure to DLL1 and no DAPT) (Supplemental
Figure 6B), and transfected these cells with anti–
MIR-143 and anti–MIR-145 LNA inhibitors, alone or in
combination (Figures 3B and 3C). Efﬁcient MIR
blockade was demonstrated by the reduced mature
MIR levels observed in transfected adult CPCs and the
up-regulation of the corresponding target genes in
these cells. CPCs receiving no inhibitors or trans-
fected with a scrambled LNA inhibitor produced
smooth muscle cells, as judged by high MYH11expression and low expression of MYH6 and MYH7 in
differentiating cells. Furthermore, CPCs transfected
with either the anti–MIR-143 or the anti–MIR-145 LNA
demonstrated a reduced capacity to produce smooth
muscle cells. These cells, however, did not give rise to
cardiomyocytes. In sharp contrast, CPCs transfected
with a combination of anti–MIR-143 and anti–MIR-
145 were characterized by up-regulation of MYH6
and MYH7, down-regulation of MYH11, and there-
fore, massively differentiate into cardiomyocytes
(Figure 3D). We subsequently evaluated whetherMIR-
143/145 expression were sufﬁcient to force CPCs to
differentiate into smooth muscle cells. For this, CPCs
were exposed to DLL1 and cultured in the presence of
DAPT, a protocol inducing cardiomyocyte production
(Supplemental Figure 6C). Untransfected CPCs or
CPCs transfected with a scrambled miRNA mimic
demonstrated high MYH6 and MYH7, and low MYH11
expression, indicating that these cells differentiated
intocardiomyocytes(SupplementalFigures6Dand6E).
On the contrary, when CPCs were transfected with
either a MIR-143 or a MIR-145 mimic, MIR-143/145
target genes were down-regulated, MYH6 and MYH7
expression was signiﬁcantly blunted, and MYH11
expression was markedly induced, showing that
CPCs were redirected into the smooth muscle
cell lineage. Altogether, these data indicated that
MIR-143 and MIR-145 were indispensable for speci-
fying adult CPCs into the smooth muscle fate.
It further demonstrated that concomitant inhibition
of the 2 miRNAs was sufﬁcient to promote cardio-
genesis in adult CPCs.
BINARY CELL FATE DECISION BETWEEN THE CARDIO-
MYOCYTE AND SMOOTH MUSCLE CELL FATES IN ADULT
CPC CLONES. In order to demonstrate the potential of
individual CPCs to adopt a cardiomyocyte and a
smooth muscle cell fate, we derived a series of clones
from proliferating adult CPCs. Figure 4 depicts results
obtained with 1 clone, representative of 15 sharing a
similar phenotype in 3 independent experiments.
This clone expressed cardiac transcription factors and
demonstrated a surface phenotype identical to that
observed for the bulk population (Figures 4A and 4B).
Although CD140a (PDGFRa) and NG2 were not
detected on the surface of the different clones, these
populations expressed homogenously CD146, con-
ﬁrming their probable pericyte origin. Furthermore,
all clones were found positive for NKX2.5, GATA4,
and MEF2C, and maintain a high proliferative capac-
ity. Importantly, provided that they were subjected
to DLL1 and DAPT during differentiation, the
clones produced large amounts of cardiomyocytes
(Figures 4D and 4E). Cardiomyocytes stained positive
FIGURE 3 NOTCH-Mediated Regulation of Cell Fate Decision Between the Smooth Muscle Cell and Cardiomyocyte Lineages Depends on MIR-143/145 Expression
(A) Expression of MIR-143 and MIR-145 in proliferating CPCs (Expansion; black) and in adult CPCs exposed to DLL1 (gray), and differentiated in the absence (upper
panels) or presence of DAPT (lower panels). Data represent mean  SEM; *p < 0.05 as compared with proliferating CPCs; ‡p < 0.05 as compared with differentiating
unstimulated (None; white) CPCs in absence of DAPT (n ¼ 5). (B) Expression of MIR-143, -145, and miRNA targets (ELK1, KLF4) in proliferating CPCs (Expansion; black)
and in differentiated adult CPCs (without prior DLL1 exposure, in the absence of DAPT). Cells were either transfected (white) or not (None; gray) with the indicated
miRNA LNA inhibitor. Data represent mean  SEM; *p < 0.05 as compared with proliferating CPCs; ‡p < 0.05 as compared with differentiating CPCs transfected with
scrambled miRNA LNA inhibitor (n ¼ 3). (C) Expression of sarcomeric proteins (MYH6, MYH7, MYH11) in proliferating CPCs (Expansion; black) and in differentiated adult
CPCs (without prior DLL1 exposure, in the absence of DAPT). Cells were transfected (white) or not (None; gray) with the indicated miRNA LNA inhibitor. Data represent
mean  SEM; *p < 0.05 as compared with proliferating CPCs; ‡p < 0.05 as compared with differentiating CPCs transfected with scrambled miRNA LNA inhibitor (Scr)
(n ¼ 3). (D) Analysis of SM-MHC and a-ACTININ expression by immunostaining in differentiated CPCs (without prior DLL1 exposure, in the absence of DAPT), transfected
or not with the indicated miRNA LNA inhibitor. Nuclei were stained with DAPI (blue). Scale bars: 50 mm. Quantiﬁcation of the numbers of a-ACTININPOS cardiomyocytes
or sm-MHCPOS smooth muscle cells. Data represent mean  SEM; *p < 0.05 as compared with proliferating CPCs; ‡p < 0.05 as compared with differentiating
CPCs transfected with scrambled miRNA LNA inhibitor (Scr) (minimum 2,000 cells in 30 different ﬁelds at a magniﬁcation of 40 per quantiﬁcation). Abbreviations as
in Figure 1.
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FIGURE 4 Analysis of Representative Human CPC Clones
(A) Flow cytometric analysis of CD31, CD34, CD45, CD73, CD90, CD105, CD117, CXCR4, CD140a, CD146, and NG2 expression in 1 CPC clone. Histograms show control
(gray) and speciﬁc ﬂuorescent intensity signal (white). (B) Analysis of cardiac transcription factor expression by immunostaining. NKX2.5 (red); MEF2C (green). Nuclei
were stained with DAPI (blue). (C) Expression of cardiac transcription factors (GATA4, MEF2C, NKX2.5), and sarcomeric proteins (MYH6, MYH7, MYH11) in proliferating
adult CPCs (Expansion; black) and in adult CPCs exposed to DLL1 (gray), and differentiated in the absence (upper panels) or presence of DAPT (lower panels). Data
represent mean  SEM; *p < 0.05 as compared with proliferating CPCs; ‡p < 0.05 as compared with differentiating unstimulated (None; white) CPCs in absence of DAPT
(n ¼ 3). (D) Analysis of SM-MHC and a-ACTININ expression by immunostaining in CPCs exposed or not to DLL1 and differentiated in the absence or presence of DAPT.
Nuclei were stained with DAPI (blue). Scale bars: 20 mm. (E) Analysis of a-ACTININ (green) and TNNI (magenta), or MLC2V (magenta) expression by immunostaining in
CPCs-derived cardiomyocytes. Nuclei were stained with DAPI (blue). Scale bars: 20 mm. (F) Cytosolic Ca2þ were recorded in CPCs-derived cardiomyocytes. Cells were
either evaluated under resting conditions, electrical stimulation (30 V, 2 ms at 5 Hz), or perfusion with caffeine. Spontaneous (top panel) and evoked (middle panel) Ca2þ
oscillations were detected. Quantiﬁcation shows the percentage of cells with spontaneous Ca2þ activity or responding to caffeine. Abbreviations as in Figure 1.
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483for a-ACTININ, troponin I (TNNI), and myosin light
chain 2v (MLC2V), showing their relative mature
phenotype. Furthermore, spontaneous and evoked
calcium transients demonstrated electrical compe-
tence (Figure 4F). The differentiated cells also
responded to caffeine, suggesting that calcium-
induced calcium release operated normally. In the
absence of this sequential NOTCH activation and in-
hibition, these clones produced exclusively smooth
muscle cells. These results demonstrated the bipo-
tential of single adult CPCs to differentiate into either
smooth muscle cells or cardiomyocytes.
CARMEN, AN ENHANCER-ASSOCIATED lncRNA,
CONTROLS MIR-143/145 EXPRESSION AND THE
SMOOTH MUSCLE CELL FATE IN ADULT CPCs. Using
transcriptome proﬁling to identify lncRNAs that
were differentially expressed in human fetal
CPCs during differentiation into cardiomyocytes,
we recently discovered CARMEN, an enhancer-
associated lncRNA (32). Importantly, CARMEN is
located in the genome immediately upstream of
MIR-143/145, and corresponds to the enhancer that
has been shown to be the target of NOTCH signaling
in smooth muscle cells (20,32). We therefore inves-
tigated whether CARMEN was implicated in lineage
determination in adult CPCs. Ten different CARMEN
isoforms have been identiﬁed. We thus named these
isoforms CARMEN1 to 10 (Figure 5A). Primers were
designed to measure individual expression of
CARMEN1, 2, 3, 6, 7, 8, 9, and 10. Speciﬁcally, we
measured the expression of each isoform in differ-
entiating fetal CPCs that gave rise to cardio-
myocytes, and in adult clonal CPCs differentiating
into either smooth muscle cells or cardiomyocytes
(Figure 5B). In adult CPCs differentiating into smooth
muscle cells, all CARMEN isoforms were either up-
regulated or not modulated. By contrast, in fetal
CPCs, a single isoform, CARMEN7, was signiﬁcantly
down-regulated during differentiation into car-
diomyocytes. In addition, expression of all isoforms
including CARMEN7 was abolished in adult CPCs
subjected to sequential NOTCH activation and inhi-
bition to promote a cardiomyocyte fate. In order
to determine whether CARMEN7 and MIR-143/145
were indeed coregulated in adult CPCs, we measured
their expression in different situations favoring
the emergence of a smooth muscle cell or a car-
diomyocyte lineage (Figure 5C). In adult CPCs
producing smooth muscle cells, CARMEN7 and
MIR-143/145were highly expressed. As a consequence,
KLF4 and ELK1 expression was minimal. By contrast,
CARMEN7 and MIR-143/145 were down-regulated
in adult CPCs speciﬁed into the cardiomyocyte fate.In this case, the levels of KLF4 and ELK1 were
elevated.
TARGETING CARMEN7 INHIBITS SMOOTH MUSCLE
COMMITMENT AND PROMOTES A CARDIOMYOCYTE
FATE IN ADULT CPCs. Since a positive correlation
existed between CARMEN7 and MIR-143/145 expres-
sion, we postulated that CARMEN7 could directly
control MIR-143/145 expression via cis-acting regula-
tion, a mechanism that is common for enhancer-
derived lncRNAs (30,43). To test this hypothesis,
we designed modiﬁed antisense oligonucleotides
(GapmeRs) targeting either all CARMEN isoforms or
speciﬁcally CARMEN7, that is, in the latter case, the
unique exon that is speciﬁc of this particular isoform.
Adult CPCs were induced to differentiate into smooth
muscle cells (no DLL1 exposure, no DAPT), a situation
in which all CARMEN isoforms are signiﬁcantly
expressed. Cells were in addition transfected with
GapmeRs directed against either all CARMEN iso-
forms or uniquely CARMEN7. The experiment
demonstrated that CARMEN7 was the only isoform
speciﬁcally down-regulated by CARMEN7 GapmeRs,
whereas the pan-CARMEN GapmeRs abolished
expression of all isoforms (Supplemental Figure 7A).
We next used these 2 different GapmeRs to evaluate
the signiﬁcance of CARMEN7 in the regulation of the
smooth muscle cell versus cardiomyocyte fate in
differentiating adult CPCs. We ﬁrst evaluated the
effects of CARMEN7 blockade on expression of MIR-
143/145 and their respective target genes. Speciﬁc
CARMEN7 knockdown resulted in a marked down-
regulation of MIR-143/145 expression, and a simulta-
neous up-regulation of ELK1 and KLF4 expression
(Figure 6A).
The role of CARMEN7 in the adoption of a
particular fate was then investigated in adult CPCs.
CPC clones were therefore cultured under differenti-
ating conditions after no or previous exposure to
DLL1, and in the absence or presence of DAPT
(Supplemental Figure 7B). Cells were transfected with
either control scrambled GapmeRs, GapmeRs target-
ing all CARMEN isoforms or CARMEN7-speciﬁc
GapmeRs. Speciﬁcation into the smooth muscle fate
was completely blocked by GapmeRs directed against
either all CARMEN isoforms or CARMEN7, as judged
in particular by the down-regulation of MYH11
expression and the marked decrease in the number
of SM-MHCPOS cells in all experimental conditions
(Figures 6B and 6C). These ﬁndings conﬁrmed
the dependence of the smooth muscle lineage on
CARMEN7 expression. The 2 GapmeRs alone did
not, however, impact signiﬁcantly cardiogenesis.
Indeed, in transfected CPCs that were not exposed to
FIGURE 5 CARMEN Transcripts Are Differentially Regulated During Fetal and Adult Differentiation Into Smooth-Muscle Cells Or Cardiomyocytes
(A) UCSC screenshot of the human CARMEN locus. The 10 CARMEN isoforms, that is, CARMEN1, 2, and 3, 4, 5, 6, 7, 8, 9, and 10 are indicated in red. The 2 miRNAs,
MIR-143/145, are indicated in green. (B) Expression of CARMEN transcripts (CARMEN1, 2, 3, 6, 7, 8, 9, 10) in proliferating (Expansion; white), and in differentiated fetal
and adult CPCs without prior DLL1 stimulation and cultured in the absence of DAPT (Differentiation; black) or after stimulation with DLL1 and cultured in presence
of DAPT (DLL1/DAPT/Differentiation; light gray). Data represent mean  SEM; *p < 0.05 as compared with proliferating CPCs (n ¼ 4). (C) Expression of CARMEN7,
MIR-143, MIR-145, ELK1, and KLF4 transcripts in proliferating CPCs (Expansion [Exp]; black) and in differentiated adult CPCs (white and light gray), exposed or not to
DLL1 in the absence or presence of DAPT. Data represent mean  SEM; *p < 0.05 as compared with proliferating CPCs; ‡p < 0.05 as compared with differentiating
unstimulated (None; white) CPCs in absence of DAPT (n ¼ 3).
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FIGURE 6 CARMEN Down-Regulation Promotes CPC Differentiation Into Cardiomyocytes
(A) Expression of CARMEN7, MIR-143 MIR-145, ELK1, and KLF4 transcripts in proliferating CPCs (Expansion [Expansion]; black) and in differentiated (Differentiation)
adult CPCs without prior DLL1 stimulation and cultured in the absence of DAPT (None No DAPT). Cells were transfected with either scrambled GapmeRs (white),
GapmeRs directed against all CARMEN isoforms (light gray), or GapmeRs directed speciﬁcally against CARMEN7 (dark gray). Data represent mean  SEM; *p < 0.05 as
compared with proliferating CPCs; ‡p < 0.05 as compared with differentiating CPCs (white) transfected with scrambled GapmeRs (n ¼ 3). (B) Expression of sarcomeric
proteins (MYH6,MYH7,MYH11) in proliferating CPCs (Expansion; black) and in differentiated adult CPCs exposed or not to DLL1 in the absence or presence of DAPT. Cells
were transfected with either scrambled GapmeRs (white), GapmeRs directed against all CARMEN isoforms (light gray), or GapmeRs directed speciﬁcally against
CARMEN7 (dark gray). Data represent mean  SEM; *p < 0.05 as compared with proliferating CPCs; ‡p < 0.05 as compared with differentiating CPCs (white)
transfected with scrambled GapmeRs (n ¼ 3). (C) Analysis of SM-MHC, a-ACTININ, TNNI, and MLC2V expression by immunostaining in differentiated CPCs exposed to
DLL1 in the presence of DAPT, transfected with either scrambled GapmeRs (white), GapmeRs directed against all CARMEN isoforms (light gray), or GapmeRs directed
speciﬁcally against CARMEN7 (dark gray). Scale bar: 25 mm. Quantiﬁcation of the numbers of a-ACTININPOS, TNNIPOS, or MLC2VPOS cardiomyocytes and sm-MHCPOS
smooth muscle cells. Data represent mean  SEM; *p < 0.05 as compared with proliferating CPCs; ‡p < 0.05 as compared with differentiating CPCs (white) transfected
with scrambled GapmeRs (minimum 1,500 cells in 20 different ﬁelds at a magniﬁcation of 40 per quantiﬁcation).
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486DLL1 and not cultured in DAPT-containing medium,
MYH6 and MYH7 expression was not different than
under controlled conditions. Nevertheless, CARMEN
knockdown strikingly reinforce the cardiogenic pro-
gram in committed cells. Large amounts of car-
diomyocytes were detected in this case. Speciﬁcally,
up to 60% of CPC clones adopted a cardiomyocyte
fate. In particular, these cells demonstrated expres-
sion of the cardiac proteins a-ACTININ, TNNI, and
myosin light chain 2 (MLC2V) (Figure 6C). Moreover,
most of the cells are characterized by the presence of
organized sarcomeres.
GENE REGULATORY NETWORK CONTROLLING CPC
DIFFERENTIATION. In order to elucidate the tran-
scriptional events associated with CPC differentia-
tion, we proﬁled the transcriptome using RNA
sequencing in differentiating fetal and adult CPCs
under various conditions (Supplemental Table 2). We
ﬁrst performed a principal component analysis of all
genes signiﬁcantly modulated in either CPCs differ-
entiating into cardiomyocytes or CPCs differentiating
into smooth muscle cells (adjusted p value <0.05)
(Figure 7A). Ninety-one percent of total variation can
be attributed to the ﬁrst 2 principal components.
Strikingly, proliferating undifferentiated fetal and
adult CPCs clustered together, consistent with the
notion that these cells demonstrated a similar
phenotype, and giving further support to previous
analysis of surface marker expression (Figure 1) (31).
In sharp contrast, differentiated fetal and adult CPCs
clearly differed in this analysis, in accordance with
their respective capacity to produce either car-
diomyocytes or smooth muscle cells. However, adult
CPCs exposed to DLL1 and induced to differentiate in
the presence of DAPT, that is, producing car-
diomyocytes, showed a shift along the PC1 and PC2
axes, and were similar to fetal CPC-derived car-
diomyocytes. Hierarchical clustering conﬁrmed that
proliferating CPCs from fetal and adult hearts share
an identical transcriptional signature (Figure 7B, 2nd
and 3rd columns). Clustering analysis then demon-
strated that genes activated in each situations giving
rise to cardiomyocytes were down-regulated during
differentiation into smooth muscle cells. Differentia-
tion into cardiomyocytes was associated with rele-
vant gene ontology (GO) terms and networks, such as
cardiac development and morphogenesis, coupled to
activation of speciﬁc cardiogenic pathways impli-
cating important modulators of cardiogenesis, in
particular NOTCH, WNT, BMP, FGF, and TGFb (Clus-
ters 3 and 4). Conversely, adult CPCs differentiating
into smooth muscle cells expressed a transcriptional
program associated with blood vessel development
(Cluster 1).In order to deﬁne a core transcriptional program
controlling differentiation into cardiomyocytes, we
ﬁrst identiﬁed genes commonly modulated during
fetal CPC differentiation and during differentiation of
adult CPCs exposed to DLL1 and DAPT. Genes that
were differentially expressed in adult CPCs differen-
tiating into smooth muscle cells were subtracted from
those that were common to both datasets (Figure 7C).
We next determined GO category enrichment for
up- and down-regulated genes. GO terms and net-
works associated with up-regulated genes (112 genes)
were representative of cardiac differentiation and
morphogenesis, and muscle contraction. On the con-
trary, negatively modulated genes (37 genes) were
associated with smooth muscle cell differentiation,
blood vessel morphogenesis, and angiogenesis. We
also analyzed GO categories in up- and down-
regulated genes, which were found uniquely modu-
lated in adult CPCs differentiating into smooth
muscle cells. Consistently, we found that up-
regulated genes (569 genes) were associated with
GO terms deﬁning development of blood vessels.
Interestingly, down-regulated genes (722 genes) were
implicated primarily in neurogenesis.
To identify processes under control of NOTCH
signaling, we next compared adult CPCs induced to
differentiate following DLL1 exposure in the absence
or presence of DAPT (Supplemental Figure 8A). GO
term enrichment in genes that were up- and down-
regulated exclusively in DLL1-sensitized CPCs
cultured in DAPT-containing medium were deter-
mined. As expected, up-regulated genes (359 genes)
were found to be implicated in cardiac development.
Consistent with a control of smooth muscle cell dif-
ferentiation by NOTCH-mediated expression of
MIR-143/145, down-regulated genes (98 genes) were
associated with blood vessel morphogenesis. Impor-
tantly, neurogenesis was also a prime target of
NOTCH inhibition. A similar approach was used to
determine processes under the control by the CAR-
MEN. We compared differentiating adult CPCs
following exposure to DLL1, transfected with either
scrambled control GapmeRs or GapmeRs directed
against all CARMEN isoforms in the absence of DAPT
(Supplemental Figure 8B). Up-regulated genes (258
genes) were involved in cardiac muscle differentia-
tion. This is in accordance with the transcriptional
signature observed in the hierarchical clustering
analysis (Figure 7B). Indeed, DLL1-activated adult
CPCs treated with GapmeRs targeting CARMEN pro-
duced a signature similar to that of cardiogenic
cells despite the fact that CARMEN-depleted
adult CPCs produced smooth muscle cells. CARMEN
down-regulation appeared to favor, therefore, the
FIGURE 7 Transcriptional Signature Activated During CPC Differentiation Into Cardiomyocytes
(A) Principal component analysis of genes differentially expressed during differentiation of CPCs into either cardiomyocytes or smooth muscle cells. Groups are indicated
in the ﬁgure. Numbers refer to Supplemental Table 2. (B) Hierarchical clustering of genes differentially expressed during differentiation of CPCs into either car-
diomyocytes or smooth muscle cells. Groups are indicated in the Figure. Gene ontology (Go) terms and biological processes annotated by Gene Go are indicated.
Continued on the next page
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487emergence of a cardiogenic program, even if
not sufﬁcient to redirect CPCs into a cardiomyocyte
fate.
Several important factors and transcriptional reg-
ulators were identiﬁed among the top modulated
genes in cardiogenic CPCs. We conﬁrmed their dif-
ferential expression in various situations by quanti-
tative RT-PCR (Supplemental Figure 8C). In
particular, HOPX, a transcription factor implicated incardiomyocyte proliferation and differentiation, was
markedly up-regulated (44). Hopx was recently
shown to control cardiogenic commitment of cardio-
vascular progenitors in the developing mouse heart
(45). Speciﬁcally, Hopx acts as a co-repressor in
the BMP4 signaling pathway to modulate WNT and
promote cardiogenesis. BMP2 and BMP4 expression
were indeed induced in CPCs differentiating into
cardiomyocytes. In addition, several WNT ligands
FIGURE 7 Continued
(C) Venn diagram of up- and down-regulated genes common or unique to fetal CPCs differentiating in cardiomyocytes (blue), adult CPCs differentiating into smooth
muscle cells (green), and adult CPCs differentiating into cardiomyocytes following exposure to DLL1 and DAPT treatment (pink). Gene ontology terms and biological
processes annotated by Gene Go are indicated for sets of genes common to cells differentiating into cardiomyocytes, and for set of genes unique to cells differentiating
into smooth muscle cells. Abbreviations as in Figure 1.
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488were modulated, in particular WNT5A and WNT11,
demonstrating a pattern of expression known to favor
cardiogenic differentiation in cardiac progenitors
(46). Key transcription factors playing crucial roles in
cardiogenesis were found also up-regulated in adult
CPCs giving rise to cardiomyocytes, such as ISL1,
IRX1, IRX2, and IRX4 (4,47). Finally, to identify po-
tential factors regulating speciﬁcation into car-
diomyocytes, we performed a predictive analysis of
upstream regulators using the gene set common to
fetal and adult CPCs producing cardiomyocytes
(Figure 7C, Supplemental Table 3). Among cytokines
and growth factors that were predicted to regulate
cardiogenic commitment, several factors were
involved in cardiomyocyte differentiation and main-
tenance of cell identity, such as BMP4, FGF2, and
CXCL12 (33,48,49), and as inducers of cell division in
cardiac myocytes such as neuregulin (NRG1), oncos-
tatin M (OSM), and interleukin (IL)13 (50,51).DISCUSSION
The rate of cardiomyocyte renewal in the adult
mammalian heart is low, and not sufﬁcient to
replenish the heart with newly formed myocytes
following injury (2). The reasons for this relative in-
capacity of the heart to induce effective regeneration
are still obscure. Many laboratories have identiﬁed
various kinds of CPCs, which demonstrate ability to
generate cardiomyocytes in vitro (3,4). However,
these cells usually have a poor capacity to produce a
functional myocardium in vivo. In the present study,
we have isolated a subpopulation of multipotent
clonogenic CPCs from human atrial appendages.
These cells demonstrate a unique pattern of surface
marker expression. Indeed, CPC clones express uni-
formly CD73, CD90, and CD105, which characterize
these cells as multipotent mesenchymal stromal cells.
In addition, the expression of CD146 suggest a
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489possible pericyte origin (37). By contrast, clones ex-
press neither NG2 nor PDGFRa (CD140a). Cardiac-
resident mesenchymal stromal cells that occupy a
perivascular adventitial niche have been described
(52). However, these cells express PDFGRa, contrary
to the adult CPCs described in our study. Moreover,
this also distinguishes them from pericytes recently
isolated from human ventricles (53). Finally, these
cells do not express CD117, CD31, CD34, CD45, and
CXCR4. More importantly, human adult CPCs coex-
pressed NKX2.5, GATA4, and MEF2C. Furthermore,
cardiac transcription factors such as TBX5 and HAND2
are up-regulated in CPCs differentiating into car-
diomyocytes. In the normal heart, 25% of resident
cardiac non-myocyte cells were found to be positive
for GATA4, MEF2C, and TBX5 (54). Interestingly,
forced expression of cardiac transcription factors, in
combination with activators of Wnt and JAK/STAT
signaling, was able to reprogram cardiac non-myocyte
cells into cardiac progenitors, and ﬁnally, rela-
tively mature cardiomyocytes (55–57). Nevertheless,
intrinsic pre-speciﬁcation in vivo is not sufﬁcient,
and cardiogenic non-myocyte cells do not contribute
new cardiomyocytes post-myocardial infarction (54).
The reason why pre-speciﬁed cells do not spontane-
ously complete cardiogenic differentiation is
currently unknown. However, our results provide a
possible scenario. It appears that adult CPCs prefer-
entially produce smooth muscle cells over car-
diomyocytes. This is in line with observations
suggesting that increased perfusion more than de
novo cardiogenesis produces beneﬁcial effects in cell
therapy for heart disease. Moreover, paracrine factors
released from the transferred cells are thought to
stimulate angiogenesis and promote repair in the
injured heart (58). Therefore, reprogramming toward
the cardiomyocyte fate might be needed in order to
reveal the full potential of adult CPCs in vivo.
Sequential activation and inhibition of NOTCH
signaling is sufﬁcient to redirect CPCs from a default
smooth muscle commitment to a differentiation into
cardiomyocytes. Importantly, results using clonal
CPC populations formally demonstrate their capacity
for development in either of 2, apparently mutually
exclusive, lineages. Prior activation of NOTCH
signaling via exposure to NOTCH ligand is a prereq-
uisite for revealing the dormant capacity of CPCs to
produce cardiomyocytes. The NOTCH pathway has
been shown to promote CPC commitment and
expansion in the developing and postnatal hearts
(9,17,18). Accordingly, we show that key cardiac
transcription factors such as NKX2.5, GATA4, MEF2C,
and TBX5 are up-regulated in human adult CPCs
exposed to DLL1, and proliferation is stimulated.This is also reminiscent of a situation observed in the
heart of transgenic mice overexpressing Jagged1, in
which the number of NKX2.5-positive CPCs is signif-
icantly increased (14). Of note, NOTCH also stimulates
proliferation in immature cardiomyocytes (39,40).
Moreover, in embryonic stem cells and in undiffer-
entiated precursors, NOTCH is known to inhibit
cardiogenesis and maturation (10,15). Our observa-
tion supports, therefore, the notion that NOTCH ac-
tivates a cardiogenic program in adult CPCs while
preventing terminal differentiation to promote
expansion. In addition, one target of NOTCH sig-
naling in adult CPCs is the locus encoding
MIR-143/145, 2 miRNAs that are known to promote
smooth muscle differentiation (20,21). Therefore,
NOTCH activates simultaneously a smooth muscle
cell program. As a consequence, NOTCH inhibition is,
on one hand, mandatory for alleviating the inhibitory
action of NOTCH on cardiogenesis and, on the other
hand, for blocking the activation of the smooth
muscle program.
In the MIR-143/145 locus, NOTCH activates
a proximal enhancer element that is associated
with different isoforms of an enhancer-associated
lncRNA. We recently named this enhancer-
associated lncRNA CARMEN, and demonstrated its
importance as a regulator of cardiac differentiation
(20,32). Enhancers are cis-regulatory genomic ele-
ments that integrate chromatin state transitions to
elicit appropriate transcriptional and cellular re-
sponses. In recent years, it has become evident that
pervasive transcription occurs at active enhancer se-
quences during different cellular contexts, in partic-
ular during speciﬁcation and differentiation (29,30).
Interestingly, the vast majority of differentially
modulated heart–enriched lncRNAs following
myocardial infarction were derived from active
enhancers (24,27). Enhancer-associated lncRNAs
activate target gene expression primarily via cis
mechanisms involving chromatin looping between
the enhancer sequences and their target genes within
neighboring or distal domains (30,43). Several
studies, including ours, demonstrated that degrada-
tion of particular enhancer-associated lncRNAs is
sufﬁcient to reduce expression of their target coding
genes (24,27). In the present study, we show that
speciﬁcation toward the smooth muscle cell fate
in adult CPCs depends on CARMEN expression.
More speciﬁcally, among the different CARMEN
isoforms that are produced upon enhancer activation,
CARMEN7 is of crucial importance. A positive corre-
lation exists in adult CPCs between CARMEN7
and MIR-143/145 expression. Moreover, CARMEN7
is down-regulated following sequential NOTCH
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490activation and inhibition resulting in the reac-
tivation of the cardiogenic program. Accordingly,
CARMEN7 knockdown results in MIR-143/145 down-
regulation and blocks differentiation of adult CPCs
into smooth muscle cells. Altogether, these data are
consistent with a cis regulation of MIR-143/145
expression by CARMEN via CARMEN7 production in
adult CPCs. Targets of MIR-143/145 that regulate
smooth muscle cell proliferation and differentiation
have been identiﬁed (21). In particular, the pluripo-
tency factor KLF4, a MIR-145 target, inhibits termi-
nal differentiation and promotes expansion of
smooth muscle cells following injury. Furthermore,
the MIR-143 target ELK-1 is known as a competitive
inhibitor of MYOCARDIN. Finally, other MIR-143/145
targets can be implicated in maintaining smooth
muscle identity. For instance, MIR-145 has been
recently shown to regulate TGFb receptor II expres-
sion in smooth muscle cells (59). TGFb is known to
drive smooth muscle differentiation (60).
The situation observed in adult CPCs is in contrast
to what is seen in fetal CPCs, in which CARMEN7
is not signiﬁcantly expressed. In fetal CPCs
spontaneously differentiating into cardiomyocytes,
MIR-143/145 expression is inversely correlated with
expression of other CARMEN isoforms, which are
indispensable for the induction of cardiogenesis (32).
It is also important to note that none of these CAR-
MEN isoforms represent the precursor of the 2 miR-
NAs. Indeed, because a negative correlation exists in
differentiating fetal CPCs between CARMEN and MIR-
143/145 expression, CARMEN induction is associated
to MIR-143/145 down-regulation, and CARMEN
depletion induces MIR-143/145 expression. Moreover,
CARMEN boundaries have been well deﬁned by
analysis of promoter-speciﬁc histone modiﬁcation
and polyA signal frequency (61,62). Isoforms of
CARMEN, and in particular CARMEN7, terminate at a
position situated upstream of the 2 miRNAs. Finally,
CARMEN regulates cardiogenesis independently of
MIR-143/145 expression in fetal CPCs (32). Altogether,
this suggests also that CARMEN transcripts other than
CARMEN7 exert trans regulatory function to initiate
the cardiogenic program. Indeed, many characterized
lncRNAs operate in trans as decoys or recruiters for
transcription factors and chromatin-remodeling
complexes. LncRNAs act efﬁciently at remote loca-
tions in the genome via their particular afﬁnity with
RNA-binding proteins such as components of the
Trithorax and Polycomb complexes to activate or
silence speciﬁc expression programs (63).
Gene clustering analysis supports the view that
smooth muscle cell speciﬁcation in adult CPCs pre-
vents expression of the cardiogenic program. GOanalysis demonstrates that cardiac differentiation is
not induced in adult CPCs not exposed to DLL1 or in
NOTCH-activated cells without following inhibition.
In these instances, MIR-143/145 expression is acti-
vated and smooth muscle cells are produced. Inter-
estingly, CARMEN down-regulation alone is not
sufﬁcient to implement cardiomyocyte production.
Strikingly, however, adult CPCs exposed to DLL1 and
transfected with anti-CARMEN GapmeRs are charac-
terized by a gene expression pattern similar to that
observed in adult CPCs differentiating into car-
diomyocytes. Therefore, cardiogenesis is initiated by
concomitant activation of the NOTCH pathway and
CARMEN down-regulation but is not productively
efﬁcient. This observation emphasizes the strength of
NOTCH-mediated inhibition on cardiac differentia-
tion and maturation. This also suggests that NOTCH
blockade exerts pro-cardiogenic effects beyond
CARMEN down-regulation and subsequent modula-
tion of MIR-143/145 expression. Our transcriptional
data indicate that neurogenesis might need to be
inhibited before the cardiogenic program can be initi-
ated. Along this line, a binary cell fate decision be-
tween the cardiac mesoderm and the neuroectoderm
has been shown to be controlled by NOTCH in embry-
onic stem cells (15). Remarkably, under conditions of
NOTCH and CARMEN inhibition, up to 60% of differ-
entiated cells are terminally differentiated car-
diomyocytes, and practically none are smooth muscle
cells. Altogether, these data suggest that NOTCH and
CARMEN cooperate to control speciﬁcation into the
cardiomyocyte and smooth muscle lineages. Within
this gene regulatory network controlling CPC differ-
entiation, MIR-143/145 down-regulation is a manda-
tory step that permits cardiomyocyte speciﬁcation.
The visual abstract proposes a schematic of the mo-
lecular pathways implicated in the control of fate in
human adult CPCs. Interestingly, HOPX is highly
induced in CPCs speciﬁed to the cardiac lineage. This
transcriptional repressor has been recently shown to
be expressed in cardiogenic cell intermediates in the
developing mouse heart (45). Hopx is necessary for
BMP4-mediated repression of Wnt signaling. Impor-
tantly, Hopx-positive cells give rise exclusively to
cardiomyocytes. It is therefore possible that reac-
tivation of this developmental pathway in adult CPCs
forces the cells to adopt a cardiomyocyte fate.
Appropriately speciﬁed CPCs produce functional
cardiomyocytes in vivo and in vitro. Cardiomyocytes
demonstrate spontaneous and triggered calcium
signals. In particular, rapid synchronized calcium
transients are readily observable in CPC-derived
cardiomyocytes following electrical stimulation,
indicating that cardiomyocytes develop electrical
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: Cellular
replacement therapies for heart disease represent promising
therapeutic approaches. However, even if improvement in
cardiac function is sometime observed, the generation of a new
myocardium in the human heart has never been demonstrated.
This has been attributed to a relative incapacity of cardiac pre-
cursor cells to produce cardiomyocytes. Long noncoding (lnc)
RNAs are emerging as master regulator of cell speciﬁcation and
differentiation. Within this context, these molecules play crucial
roles in generating cell-speciﬁc programs, which regulate cell
identity. These properties can be utilized to program precursor
cells to adopt a cardiomyocyte fate.
TRANSLATIONAL OUTLOOK: Future research should
take advantage of the high potential of lncRNAs to regulate
cell-speciﬁc patterns of gene expression to control the
fate of precursor cells used in cell therapies and improved
cardiomyocyte production in the damaged heart.
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491competence similar to that of mature cardio-
myocytes. Furthermore, CPCs differentiate into car-
diomyocytes in vivo. These cells engraft in the
mouse post-natal heart and form structures that
appear functionally integrated in the host myocar-
dium. These ﬁndings indicate that the atrial
appendage–derived CPCs described in the present
study could represent a valuable source of pre-
cursors in cell replacement therapy for heart disease.
Provided that NOTCH is inhibited following CPC
injection into the damaged myocardium, car-
diomyocytes could be produced at the site of injury.
In this regard, although unspeciﬁc g-secretase in-
hibitors can produce toxicity in vivo, in particular in
the gut, this difﬁculty can be overcome using
selective blockers of NOTCH receptor paralogs (41).
We have indeed tested this possibility, and demon-
strated that NRR1 antibodies can substitute for DAPT
during production of CPC-derived cardiomyocytes.
Finally, we recently demonstrated that CARMEN is
induced in human cardiac pathologies and in mouse
models of cardiac disease (32). In this context, it
would be interesting to evaluate whether manipu-
lation of endogenous cardiogenic mesenchymal
precursors in vivo via modulation of the NOTCH-
CARMEN-MIR-143/145 axis is able to favor cardio-
myocyte renewal in the damaged heart, and promotes
true heart regeneration.
CONCLUSIONS AND LIMITATIONS
With the advent of reprogramming technologies, a
novel approach to regeneration has emerged. In the
context of our study, reprogramming particularly
pertains to the controlled differentiation of CPCs into
speciﬁc cardiac cells. Our study demonstrates that
the subclass of lncRNAs that are associated to
enhancer sequences can be manipulated to specify
human CPCs into particular fates. Moreover, our
ﬁndings suggest that the different lncRNA isoforms,
produced by a single locus, regulate distinct gene
programs, producing therefore diverse cellular re-
sponses. LncRNA isoform-speciﬁc effects certainly
warrant further investigation. Altogether, these
ﬁndings open new perspectives for the treatment of
heart disease, and more speciﬁcally in cell replace-
ment therapies. Several points should be however
considered. MIR-143/145 are most likely not the sole
targets of CARMEN transcripts. Within the frame of
our study, we have not investigated trans mecha-
nisms of actions. LncRNAs are known to regulate
gene transcription at remote locations in the genome,
different from their own site of transcription.In addition, LncRNAs can translocated into the
cytoplasm whether they can associate with speciﬁc
modulators of cell identity and behavior. Further-
more, NOTCH signaling exerts also a variety of ac-
tions that should be investigated. This integrated
network implicating a signaling pathway, lncRNAs
and miRNAs provide nevertheless a fascinating
example of the complexity of the molecular mecha-
nisms that regulate cell plasticity in organs such as
the heart.
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